These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 23525694)

  • 1. A multicenter phase II study of S-1 for gemcitabine-refractory biliary tract cancer.
    Suzuki E; Ikeda M; Okusaka T; Nakamori S; Ohkawa S; Nagakawa T; Boku N; Yanagimoto H; Sato T; Furuse J
    Cancer Chemother Pharmacol; 2013 May; 71(5):1141-6. PubMed ID: 23525694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multicenter phase II study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory to gemcitabine.
    Sasaki T; Isayama H; Nakai Y; Mizuno S; Yamamoto K; Yagioka H; Yashima Y; Kawakubo K; Kogure H; Togawa O; Matsubara S; Ito Y; Sasahira N; Hirano K; Tsujino T; Toda N; Tada M; Omata M; Koike K
    Invest New Drugs; 2012 Apr; 30(2):708-13. PubMed ID: 20924641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Multicenter Phase II Study of Gemcitabine plus S-1 Chemotherapy for Advanced Biliary Tract Cancer.
    Arima S; Shimizu K; Okamoto T; Toki M; Suzuki Y; Okano N; Naruge D; Kawai K; Kobayashi T; Kasuga A; Kitamura H; Takasu A; Nagashima F; Sugiyama M; Furuse J
    Anticancer Res; 2017 Feb; 37(2):909-914. PubMed ID: 28179351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A retrospective study of S-1 monotherapy as second-line treatment for patients with advanced biliary tract cancer.
    Kobayashi S; Ueno M; Ohkawa S; Andou T; Kameda R; Yamamoto N; Morinaga S
    Jpn J Clin Oncol; 2012 Sep; 42(9):800-6. PubMed ID: 22826349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized phase II study of gemcitabine plus S-1 combination therapy vs. S-1 in advanced biliary tract cancer: Japan Clinical Oncology Group Study (JCOG0805).
    Takashima A; Morizane C; Ishii H; Nakamura K; Fukuda H; Okusaka T; Furuse J
    Jpn J Clin Oncol; 2010 Dec; 40(12):1189-91. PubMed ID: 20630899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An analysis of a second-line S-1 monotherapy for gemcitabine-refractory biliary tract cancer.
    Katayose Y; Ohtsuka H; Kitamura Y; Masuda K; Nakagawa K; Yamamoto K; Yoshida H; Onogawa T; Motoi F; Naitoh T; Rikiyama T; Egawa S; Unno M
    Hepatogastroenterology; 2012 May; 59(115):691-5. PubMed ID: 22469710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of S-1 following gemcitabine with cisplatin for advanced biliary tract cancer.
    Inoue H; Todaka A; Yamazaki K; Fushiki K; Shirasu H; Kawakami T; Tsushima T; Hamauchi S; Yokota T; Machida N; Fukutomi A; Onozawa Y; Andoh A; Yasui H
    Invest New Drugs; 2021 Oct; 39(5):1399-1404. PubMed ID: 33835357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of gemcitabine and S-1 combination chemotherapy in patients with metastatic biliary tract cancer.
    Kim HS; Kim HY; Zang DY; Oh HS; Jeon JY; Cho JW; Park CK; Kim JH; Kim MJ; Ha HI; Kim JH; Han B; Song H; Kwon JH; Choi DR; Jung JY
    Cancer Chemother Pharmacol; 2015 Apr; 75(4):711-8. PubMed ID: 25630414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial.
    Morizane C; Okusaka T; Mizusawa J; Katayama H; Ueno M; Ikeda M; Ozaka M; Okano N; Sugimori K; Fukutomi A; Hara H; Mizuno N; Yanagimoto H; Wada K; Tobimatsu K; Yane K; Nakamori S; Yamaguchi H; Asagi A; Yukisawa S; Kojima Y; Kawabe K; Kawamoto Y; Sugimoto R; Iwai T; Nakamura K; Miyakawa H; Yamashita T; Hosokawa A; Ioka T; Kato N; Shioji K; Shimizu K; Nakagohri T; Kamata K; Ishii H; Furuse J;
    Ann Oncol; 2019 Dec; 30(12):1950-1958. PubMed ID: 31566666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I trial of S-1 every other day in combination with gemcitabine/cisplatin for inoperable biliary tract cancer.
    Uwagawa T; Sakamoto T; Abe K; Okui N; Hata D; Shiba H; Futagawa Y; Aiba K; Yanaga K
    Cancer Chemother Pharmacol; 2015 Jan; 75(1):191-6. PubMed ID: 25422155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I study for adjuvant chemotherapy of gemcitabine plus S-1 in patients with biliary tract cancer undergoing curative resection without major hepatectomy (KHBO1202).
    Yanagimoto H; Toyokawa H; Sakai D; Wada H; Satoi S; Yamamoto T; Nagano H; Toyoda M; Ajiki T; Satake H; Tsuji A; Miyamoto A; Tsujie M; Takemura S; Yanagihara K; Ioka T
    Cancer Chemother Pharmacol; 2018 Mar; 81(3):461-468. PubMed ID: 29305639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gemcitabine and S-1 versus gemcitabine and cisplatin treatment in patients with advanced biliary tract cancer: a multicenter retrospective study.
    Takahara N; Isayama H; Nakai Y; Sasaki T; Ishigaki K; Saito K; Akiyama D; Uchino R; Mizuno S; Yagioka H; Kogure H; Togawa O; Matsubara S; Ito Y; Toda N; Tada M; Koike K
    Invest New Drugs; 2017 Jun; 35(3):269-276. PubMed ID: 28124197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer.
    Morizane C; Okusaka T; Furuse J; Ishii H; Ueno H; Ikeda M; Nakachi K; Najima M; Ogura T; Suzuki E
    Cancer Chemother Pharmacol; 2009 Jan; 63(2):313-9. PubMed ID: 18398614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized phase II study of S-1 plus oral leucovorin versus S-1 monotherapy in patients with gemcitabine-refractory advanced pancreatic cancer.
    Ueno M; Okusaka T; Omuro Y; Isayama H; Fukutomi A; Ikeda M; Mizuno N; Fukuzawa K; Furukawa M; Iguchi H; Sugimori K; Furuse J; Shimada K; Ioka T; Nakamori S; Baba H; Komatsu Y; Takeuchi M; Hyodo I; Boku N
    Ann Oncol; 2016 Mar; 27(3):502-8. PubMed ID: 26681680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I trial of oral S-1 combined with hepatic arterial infusion of gemcitabine in unresectable biliary tract cancer.
    Ishiwatari H; Hayashi T; Yoshida M; Ono M; Sato T; Miyanishi K; Sato Y; Takimoto R; Kobune M; Kato J
    Cancer Chemother Pharmacol; 2015 Apr; 75(4):805-12. PubMed ID: 25687990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.
    Abdel-Rahman O; Elsayed Z; Elhalawani H
    Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011746. PubMed ID: 29624208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single-institution experience with gemcitabine-cisplatin combination therapy as a second-line treatment for patients with unresectable biliary tract cancer after failure of gemcitabine-S-1 combination therapy: a prospective feasibility study.
    Matsuyama R; Morioka D; Mori R; Hiratani S; Yabushita Y; Ota Y; Kumamoto T; Taniguchi K; Endo I
    Cancer Chemother Pharmacol; 2018 May; 81(5):949-955. PubMed ID: 29594362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. S-1 monotherapy as second-line treatment for advanced pancreatic cancer after gemcitabine failure.
    Todaka A; Fukutomi A; Boku N; Onozawa Y; Hironaka S; Yasui H; Yamazaki K; Taku K; Machida N; Sakamoto T; Tomita H
    Jpn J Clin Oncol; 2010 Jun; 40(6):567-72. PubMed ID: 20189975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, double-blind, phase II study of oral histone deacetylase inhibitor resminostat plus S-1 versus placebo plus S-1 in biliary tract cancers previously treated with gemcitabine plus platinum-based chemotherapy.
    Ueno M; Morizane C; Furukawa M; Sakai D; Komatsu Y; Nakai Y; Tsuda M; Ozaka M; Mizuno N; Muto M; Fukutomi A; Ikeda M; Tsuji A; Katanuma A; Moriwaki T; Kajiwara T; Ishii H; Negoro Y; Shimizu S; Nemoto N; Kobayashi S; Makino K; Furuse J
    Cancer Med; 2021 Mar; 10(6):2088-2099. PubMed ID: 33635605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A feasibility study of gemcitabine, S-1 and leucovorin combination therapy (GSL) for advanced biliary tract cancer.
    Takahara N; Isayama H; Nakai Y; Sasaki T; Saito K; Sato T; Hakuta R; Ishigaki K; Saito T; Hamada T; Mizuno S; Kogure H; Tada M; Koike K
    J Chemother; 2019 Sep; 31(5):284-289. PubMed ID: 31179889
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.